EMBOTAPE ORAL PASTE 400 MG/G

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

PYRANTEL EMBONATE

Available from:

Cross Vetpharm Group Limited

ATC code:

QP52AF02

INN (International Name):

PYRANTEL EMBONATE

Dosage:

400 mg/g

Pharmaceutical form:

Oral Paste

Prescription type:

LM-Licensed Merchant

Therapeutic group:

Equine - Food

Therapeutic area:

Pyrantel

Therapeutic indications:

Endoparasiticide

Authorization status:

Authorised

Authorization date:

1998-01-09

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Embotape Oral Paste 400 mg/g
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each syringe contains:
ACTIVE SUBSTANCE
PER 28.5 G SYRINGE
PER 57 G SYRINGE
Pyrantel embonate
11.4 g
22.8 g
EXCIPIENTS
Butylated Hydroxytoluene (E321)
0.0057 g
0.0114 g
For a full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Oral paste.
A pale coloured to buff coloured paste.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and ponies.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the control and treatment of adult infections of large and small _Strongyles, Oxyuris, Parascaris _and _Anoplocephala_
_perfoliata._
4.3 CONTRAINDICATIONS
Do not use in severely debilitated animals.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 27/11/2013_
_CRN 7016469_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Only intended for direct oral administration.
The same syringe should only be used to dose two animals if they are both healthy and are either running together, or
are on the same premises and in direct contact with each other.
As with other anthelmintics, veterinary advice should be sought on appropriate dosing programmes and stock
management to achieve adequate parasite control and reduce the likelihood of anthelmintic resistance developing.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could
ultimately result in ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class over an extended period of time.
•
Underdosing, which may be due to under-estimation of the bodyweight, mis-administration of the product or lack